Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Affimed validates antibody target for cancer metastasis
Results published in current issue of the Journal of Molecular Biology

Heidelberg, Germany - May 13, 2008 - Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, announced today that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. The target, 37 kDa/67 kDa laminin receptor precursor and/ or its receptor, is overexpressed in cancer cell lines and their metastatic potential correlates with LRP/LR levels. Affimed was able to demonstrate that an antibody targeting this receptor could reduce invasive potential by up to 40% and adhesion by up to 70%. This study was published on May 2nd in the Journal of Molecular Biology*.

LRP/LR acts as a receptor for prions and viruses, but has also been shown to be overexpressed in metastatic cancer tissue. In the present study, it was challenged in a metastatic cancer cell line with a variety of therapeutic strategies including single chain and full IgG antibodies, siRNAs and small molecules (polysulfated glycanes).The effects on the invasive and adhesive properties of the cells were examined using in vitro models of cell migration. Invasion and adhesion are the processes by which cancer cells metastasize and spread to multiple other regions of the body. The single chain and full length antibodies were able to reduce invasion by 30% and 40%, respectively, and adhesion by 60% and 70%, respectively.

Prof. Melvyn Little, CSO of Affimed commented: 'Our data suggest that reagents directed against LRP/LR, in particular antibodies, might be potential cancer therapeutics blocking metastases. Once again we have been able to demonstrate Affimed's competence in generating new, fully human antibodies against innovative targets.'

Further data concerning this collaboration has also been accepted for publication later this year in the Journal of General Virology. Affimed has a pipeline of preclinical cancer antibodies, poised to enter the clinic, and a number of other early stage projects including this.

* Zuber, C., Knackmuss, S., Zemora , G., Reusch, U., Vlasova, E., Diehl, D., Mick , V., Hofmann, K., Nikles, D., Fröhlich, T., Arnold, G., Brenig, B., Wolf, E., Lahm, H., Little, M., & Weiss, S. (2008) Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37 kDa/67 kDa laminin receptor. Journal of Molecular Biology,Volume 378, Issue 3, 2 May 2008, Pages 530-539

About Affimed Therapeutics AG
Affimed is a private biopharmaceutical company based in Heidelberg, Germany specialising in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg. By utilizing its broad portfolio of proprietary, in-house technology platforms together with crucial enabling freedom-to-operate licenses, the company has been able to establish a pre-clinical product pipeline of promising novel product candidates mainly for indications in oncology and autoimmune diseases. To learn more about Affimed please visit

Further Information:

Prof. Dr Melvyn Little
Chief Scientific Officer
Affimed Therapeutics AG
t: +49 (0)6221 65307 20

Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06

Publisher Contact Information:

Affimed Therapeutics AG
+49 (0)6221 65307 20

Company profile of Affimed Therapeutics AG
Past press releases of Affimed Therapeutics AG.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.